Form 4: ATAI Life Sciences Director Angermayer Acquires Stock Options
SEC Form 4 Filing
Christian Angermayer, a director and 10% owner of ATAI Life Sciences N.V., acquired 103,000 stock options on June 13, 2024.
Summary
- Christian Angermayer, a director and 10% owner of ATAI Life Sciences N.V. (ATAI), acquired 103,000 stock options on June 13, 2024.
- The stock options have an exercise price of $1.34.
- The options vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 13, 2025.
- The options expire on June 13, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider ownership can be a positive signal, but this is a routine filing.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This transaction reflects the director's investment in the company's equity.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Christian Angermayer acquired 103,000 stock options. |
| 06/13/2025 | Stock options vest on the earlier of the day before the next annual meeting or this date. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.